

**Publications:**

1. UJ Buchholz *et al.* Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. *J Virol.* 2000 Feb;74(3):1187–1199.

2. A Karger *et al.* Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. *J Gen Virol.* 2001 Mar;82(Pt 3):631–640.

3. UJ Buchholz *et al.* Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. *J Virol.* 1999 Jan;73(1):251–259.

**Patent Status:**

HHS Reference No. E-178-1999/0—

- International Patent Application PCT/US00/17755, which published as WO 2001/04335 on 09 Jan 2001 (expired)
- Australian Patent 784216
- Chinese Patent 00810119.1
- Canadian Patent Application 2378552
- European Patent Application 00941756.9
- Israeli Patent Application 147447
- Japanese Patent Application 2001-509539
- Korean Patent Application 10-2002-7000318
- Mexican Patent Application 2002-000220
- Brazilian Patent Application PI0013195-4 and
- Chinese Patent Application 200710167112.6

HHS Reference No. E-178-1999/1—

- U.S. Patent Application No. 11/097,946 filed 31 Mar 2005

HHS Reference No. E-178-1999/2—

- U.S. Patent Application No. 10/704,116 filed 07 Nov 2003

**Licensing Status:** Available for licensing.

**Licensing Contact:** Michael A. Shmilovich, Esq.; 301-435-5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

**Collaborative Research Opportunity:** The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize attenuated live vaccines against respiratory syncytial virus (RSV). Please contact Barry Buchbinder at 301-594-1696 for more information.

Dated: September 9, 2008.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E8-21519 Filed 9-15-08; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director's Consumer Liaison Group.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

**Name of Committee:** National Cancer Institute Director's Consumer Liaison Group.  
**Date:** October 14–15, 2008.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** (1) Approval of Minutes; (2) Report from Dr. John Niederhuber, NCI Director; (3) Report on the OAR; (4) Report from Planning & Office of Governmental & Congressional Relations OD/NCI; (5) Indian Health Service & Cancer Issues of Native Americans; (6) Cancer Health Communications; (7) Update-NCI Community Cancer Clinics Program; (8) Reports from DCLG Working Groups & Member Updates; (9) Public Comment; (10) Action Items/Conclusion.

**Place:** National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

**Contact Person:** Shannon K. Bell, MSW, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 10A30D, Bethesda, MD 20892, 301-451-3393.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [http://](http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm)

[deainfo.nci.nih.gov/advisory/dclg/dclg.htm](http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: September 9, 2008.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E8-21499 Filed 9-15-08; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Board of Scientific Advisors.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

**Name of Committee:** National Cancer Institute Board of Scientific Advisors.

**Date:** November 6–7, 2008.

**Time:** November 6, 2008, 8 a.m. to 6 p.m.

**Agenda:** Director's Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentation; Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

**Place:** National Institutes of Health, Building 31, 31 Center Drive, 6th Floor, Conference Room 10, Bethesda, MD 20892.

**Time:** November 7, 2008, 8:30 a.m. to 12 p.m.

**Agenda:** Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

**Place:** National Institutes of Health, Building 31, 31 Center Drive, 6th Floor, Conference Room 10, Bethesda, MD 20892.

**Contact Person:** Paulette S. Gray, PhD, Executive Secretary, Director, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Rm. 8001, Bethesda, MD 20892, 301-496-5147, [grayp@mail.nih.gov](mailto:grayp@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding